The complexity of sunitinib dosing in renal cell cancer patients

by Desar, Ingrid M.E., Mulder, Sasja F., Mulders, Peter F.A., van Herpen, Carla M.L.
Published in Transl Androl Urol (2012)

Theranostic applications of antibodies in oncology

by Fleuren, Emmy D.G., Versleijen-Jonkers, Yvonne M.H., Heskamp, Sandra, van Herpen, Carla M.L., Oyen, Wim J.G., van der Graaf, Winette T.A., Boerman, Otto C.
Published in Mol Oncol (2014)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study

by van Boxtel, Wim, Lütje, Susanne, van Engen-van Grunsven, Ilse C.H., Verhaegh, Gerald W., Schalken, Jack A., Jonker, Marianne A., Nagarajah, James, Gotthardt, Martin, van Herpen, Carla M.L.
Published in Theranostics (2020)

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

by Mulder, Sasja F, Bertens, Dirk, Desar, Ingrid ME, Vissers, Kris CP, Mulders, Peter FA, Punt, Cornelis JA, van Spronsen, Dick-Johan, Langenhuijsen, Johan F, Kessels, Roy PC, van Herpen, Carla ML
Published 2014

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

by Küsters-Vandevelde, Heidi VN, Willemsen, Annelieke ECAB, Groenen, Patricia JTA, Küsters, Benno, Lammens, Martin, Wesseling, Pieter, Djafarihamedani, Melika, Rijntjes, Jos, Delye, Hans, Willemsen, Michel A, van Herpen, Carla ML, Blokx, Willeke AM
Published 2014

Merkel Cell Carcinoma: New Trends

by Zwijnenburg, Ellen M., Lubeek, Satish F.K., Werner, Johanna E.M., Amir, Avital L., Weijs, Willem L.J., Takes, Robert P., Pegge, Sjoert A.H., van Herpen, Carla M.L., Adema, Gosse J., Kaanders, Johannes H. A. M.
Published in Cancers (Basel) (2021)

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue

by Prinsen, Hetty, van Laarhoven, Hanneke WM, Pots, Jeanette M, Duiveman-de Boer, Tjitske, Mulder, Sasja F, van Herpen, Carla ML, Jacobs, Joannes FM, Leer, Jan Willem H, Bleijenberg, Gijs, Stelma, Foekje F, Torensma, Ruurd, de Vries, I Jolanda M
Published in Hum Vaccin Immunother (2015)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

by van Herpen, Carla M.L., Agarwala, Sanjiv S., Hauschild, Axel, Berking, Carola, Beck, J. Thaddeus, Schadendorf, Dirk, Jansen, Rob, Queirolo, Paola, Ascierto, Paolo A., Blank, Christian U., Heinrich, Michael C., Pal, Rupam R., Derti, Adnan, Antona, Victor, Nauwelaerts, Heidi, Zubel, Angela, Dummer, Reinhard
Published in Oncotarget (2019)

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

by Lesterhuis, W. Joost, Punt, Cornelis J.A., Hato, Stanleyson V., Eleveld-Trancikova, Dagmar, Jansen, Bastiaan J.H., Nierkens, Stefan, Schreibelt, Gerty, de Boer, Annemiek, Van Herpen, Carla M.L., Kaanders, Johannes H., van Krieken, Johan H.J.M., Adema, Gosse J., Figdor, Carl G., de Vries, I. Jolanda M.
Published 2011

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity

by Hato, Stanleyson V., Figdor, Carl G., Takahashi, Susumu, Pen, Anja E., Halilovic, Altuna, Bol, Kalijn F., Vasaturo, Angela, Inoue, Yukie, de Haas, Nienke, Verweij, Dagmar, Van Herpen, Carla M.L., Kaanders, Johannes H., van Krieken, Johan H.J.M., Van Laarhoven, Hanneke W.M., Hooijer, Gerrit K.J., Punt, Cornelis J.A., Asai, Akira, de Vries, I. Jolanda M., Lesterhuis, W.J.
Published in Oncotarget (2017)